Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AWD 131-138 is a partial agonist of the GABAA receptor that acts at the benzodiazepine binding site, dose-dependently stimulating GABA currents with a threshold of 0.3-1.0 µM.1 This effect is blocked by the benzodiazepine antagonist flumazenil (Item No. 14252).1 AWD 131-138 displays a broad spectrum of anticonvulsant activity in diverse seizure and epilepsy models without a tendency toward tolerance or abuse.2,3,4 It has a superior pharmacokinetic profile in dogs vs. humans.3,5
WARNING This product is not for human or veterinary use.
1. The antiepileptic drug AWD 131-
2. Imepitoin as novel treatment option for canine idiopathic epilepsy: Pharmacokinetics, distribution, and metabolism in dogs. J. Vet. Pharmacol. Ther. 37(5), 421-434 (2015).
3. The pharmacology of imepitoin: The first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs 28(1), 29-43 (2014).
4. Evaluation of the novel antiepileptic drug, AWD 131-
5. Canine epilepsy: An underutilized model. ILAR J. 55(1), 182-186 (2014).